{"filing":{"accession_number":"0000200406-26-000163","cik":"0000200406","ticker":"JNJ","company_name":"JOHNSON \u0026 JOHNSON","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"jnj-20260729.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/200406/000020040626000163/jnj-20260729.htm"},"events":[{"id":21805,"run_id":19675,"accession_number":"0000200406-26-000163","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Johnson \u0026 Johnson announced completion of the acquisition of Firefly Bio, Inc. for $1 billion in cash and entry into strategic agreements with Sail Biomedicines (including a $2.58 billion acquisition option). These are material M\u0026A transactions that directly impact the company's financial guidance, reducing 2026 Adjusted Operational EPS by $0.64 and 2027 EPS by $1.36. The Item 7.01 disclosure centers on the completion of these acquisitions and the resulting guidance updates, which are hallmarks of ma_activity.","company_name":"JOHNSON \u0026 JOHNSON","ticker":"JNJ","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21532,"accession_number":"0000200406-26-000163","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Johnson \u0026 Johnson announced completion of the acquisition of Firefly Bio, Inc. for $1 billion in cash and entry into strategic agreements with Sail Biomedicines (including a $2.58 billion acquisition option). These are material M\u0026A transactions that directly impact the company's financial guidance, reducing 2026 Adjusted Operational EPS by $0.64 and 2027 EPS by $1.36. The Item 7.01 disclosure centers on the completion of these acquisitions and the resulting guidance updates, which are hallmarks of ma_activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:22:02.864743+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21532,"accession_number":"0000200406-26-000163","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Johnson \u0026 Johnson announced completion of the acquisition of Firefly Bio, Inc. for $1 billion in cash and entry into strategic agreements with Sail Biomedicines (including a $2.58 billion acquisition option). These are material M\u0026A transactions that directly impact the company's financial guidance, reducing 2026 Adjusted Operational EPS by $0.64 and 2027 EPS by $1.36. The Item 7.01 disclosure centers on the completion of these acquisitions and the resulting guidance updates, which are hallmarks of ma_activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:22:02.864743+00:00","company_name":"JOHNSON \u0026 JOHNSON","ticker":"JNJ","filing_date":"2026-07-29"}]}